EiPLA

Last updated

EiPLA
EiPLA.svg
EiPLA 3D.png
Clinical data
Other namesEiPLA; Ethylisopropyllysergamide; N-Ethyl-N-isopropyllysergamide; Lysergic acid ethylisopropylamide
Routes of
administration 		Oral [1]
Drug class Serotonin receptor modulator; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
Legal status
Legal status
Identifiers
  • (6aR,9R)-N-ethyl-7-methyl-N-propan-2-yl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
CAS Number
PubChem CID
Chemical and physical data
Formula C21H27N3O
Molar mass 337.467 g·mol−1
3D model (JSmol)
  • CCN(C(C)C)C(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C
  • InChI=1S/C21H27N3O/c1-5-24(13(2)3)21(25)15-9-17-16-7-6-8-18-20(16)14(11-22-18)10-19(17)23(4)12-15/h6-9,11,13,15,19,22H,5,10,12H2,1-4H3/t15-,19-/m1/s1
  • Key:JLPRDEGOBAGMHN-DNVCBOLYSA-N

EiPLA, also known as N-ethyl-N-isopropyllysergamide or as lysergic acid ethylisopropylamide, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD). [2] [3] [1] It is an isomer of ETH-LAD. [1]

Contents

Use and effects

EiPLA has been identified in blotter containing doses of 86 to 97 μg base equivalent per tab. [1] Blotter containing 200 μg per tab has also been described. [1] Anecdotal reports suggest that EiPLA produces psychedelic effects but is less potent than LSD. [1]

Interactions

Pharmacology

Pharmacodynamics

In drug discrimination tests in rodents, EiPLA was found to have approximately half the potency of LSD. [2] [3] [1]

Chemistry

Analogues

Analogues of EiPLA include MiPLA, LAMPA (MPLA), EPLA, EcPLA, and ETFELA, among others. [1] [4]

History

EiPLA was first described in the scientific literature by David E. Nichols and colleagues by at least 1994. [2] It appears to have emerged as a novel designer drug by 2019. [1]

See also

References

  1. 1 2 3 4 5 6 7 8 9 Brandt SD, Kavanagh PV, Westphal F, Pulver B, Schwelm HM, Stratford A, et al. (February 2024). "Analytical and behavioral characterization of N-ethyl-N-isopropyllysergamide (EIPLA), an isomer of N6 -ethylnorlysergic acid N,N-diethylamide (ETH-LAD)". Drug Testing and Analysis. 16 (2): 187–198. doi:10.1002/dta.3530. PMID   37321559.
  2. 1 2 3 Huang X, Marona-Lewicka D, Pfaff RC, Nichols DE (March 1994). "Drug discrimination and receptor binding studies of N-isopropyl lysergamide derivatives". Pharmacology, Biochemistry, and Behavior. 47 (3): 667–673. doi:10.1016/0091-3057(94)90172-4. PMID   8208787.
  3. 1 2 Nichols DE (October 2018). "Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD)". ACS Chemical Neuroscience. 9 (10): 2331–2343. doi:10.1021/acschemneuro.8b00043. PMID   29461039.
  4. ↑ Wachełko O, Nowak K, Tusiewicz K, Zawadzki M, Szpot P (January 2025). "A highly sensitive UHPLC-MS/MS method for determining 15 designer LSD analogs in biological samples with application to stability studies". Analyst. 150 (2): 290–308. doi:10.1039/d4an01361a. PMID   39636448.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.